ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
ReShape Lifesciences (RSLS) has received a USPTO Notice of Allowance for patent application 18/069,689, titled 'High-Frequency Low Duty Cycle Patterns for Neural Regulation', providing protection until August 2037. The patent covers their Diabetes Neuromodulation system which utilizes proprietary vBloc™ technology for treating Type 2 diabetes through vagal nerve modulation.
The technology features an energy-efficient algorithm that uses discontinuous high-frequency signals with interwoven micro- and millisecond pauses, consuming 10 times less energy than traditional continuous signals. Preclinical testing on rat vagus nerves has shown equivalent efficacy while remaining compatible with standard implantable pulse generators.
The company's intellectual property portfolio includes 63 issued or pending patents covering vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth-enabled applications.
ReShape Lifesciences (RSLS) ha ricevuto una Notifica di Concessione dalla USPTO per la domanda di brevetto 18/069,689, intitolata 'Pattern ad Alta Frequenza e Basso Ciclo di Lavoro per la Regolazione Neurale', che garantisce protezione fino ad agosto 2037. Il brevetto riguarda il loro sistema di Neuromodulazione per il Diabete, che utilizza la tecnologia proprietaria vBloc™ per il trattamento del diabete di tipo 2 attraverso la modulazione del nervo vago.
La tecnologia si basa su un algoritmo a basso consumo energetico che impiega segnali ad alta frequenza discontinui con pause integrate di micro e millisecondi, consumando 10 volte meno energia rispetto ai segnali continui tradizionali. I test preclinici sul nervo vago di ratto hanno dimostrato un’efficacia equivalente, mantenendo la compatibilità con i generatori di impulsi impiantabili standard.
Il portafoglio di proprietà intellettuale dell’azienda comprende 63 brevetti concessi o in attesa che coprono la neuromodulazione vagale, la regolazione del glucosio, l’intelligenza artificiale e applicazioni abilitate al Bluetooth.
ReShape Lifesciences (RSLS) ha recibido una Notificación de Aprobación de la USPTO para la solicitud de patente 18/069,689, titulada 'Patrones de Alta Frecuencia y Bajo Ciclo de Trabajo para la Regulación Neural', que brinda protección hasta agosto de 2037. La patente cubre su sistema de Neuromodulación para Diabetes que utiliza la tecnología propietaria vBloc™ para tratar la diabetes tipo 2 mediante la modulación del nervio vago.
La tecnología cuenta con un algoritmo eficiente en energía que usa señales discontinuas de alta frecuencia con pausas entrelazadas de micro y milisegundos, consumiendo 10 veces menos energía que las señales continuas tradicionales. Las pruebas preclínicas en nervios vagos de ratas han mostrado una eficacia equivalente, manteniendo la compatibilidad con generadores de impulsos implantables estándar.
El portafolio de propiedad intelectual de la empresa incluye 63 patentes otorgadas o en trámite que cubren neuromodulación vagal, regulación de glucosa, inteligencia artificial y aplicaciones habilitadas con Bluetooth.
ReShape Lifesciences (RSLS)는 '신경 조절을 위한 고주파 저듀티 사이클 패턴'이라는 제목의 특허 출원 번호 18/069,689에 대해 USPTO 허가 통지를 받았으며, 2037년 8월까지 보호를 제공합니다. 이 특허는 자사의 당뇨병 신경조절 시스템에 대한 것으로, 독점적인 vBloc™ 기술을 사용해 미주신경 조절을 통해 제2형 당뇨병을 치료합니다.
이 기술은 미세 및 밀리초 단위의 휴지 시간을 포함한 불연속 고주파 신호를 사용하는 에너지 효율적인 알고리즘을 특징으로 하며, 기존의 연속 신호보다 10배 적은 에너지를 소비합니다. 쥐의 미주신경을 대상으로 한 전임상 시험에서 동등한 효능을 보였으며, 표준 이식형 펄스 발생기와 호환됩니다.
회사의 지적 재산 포트폴리오에는 미주신경 조절, 혈당 조절, 인공지능, 블루투스 지원 애플리케이션을 포함한 63건의 등록 또는 출원 중인 특허가 포함되어 있습니다.
ReShape Lifesciences (RSLS) a reçu un avis d’acceptation de la USPTO pour la demande de brevet 18/069,689, intitulée « Motifs à haute fréquence et faible cycle de service pour la régulation neuronale », offrant une protection jusqu’en août 2037. Le brevet couvre leur système de neuromodulation du diabète qui utilise la technologie propriétaire vBloc™ pour traiter le diabète de type 2 par modulation du nerf vague.
La technologie comprend un algorithme économe en énergie utilisant des signaux haute fréquence discontinus avec des pauses entrelacées de micro- et millisecondes, consommant 10 fois moins d’énergie que les signaux continus traditionnels. Les tests précliniques sur les nerfs vagues de rats ont montré une efficacité équivalente tout en restant compatibles avec les générateurs d’impulsions implantables standards.
Le portefeuille de propriété intellectuelle de la société comprend 63 brevets délivrés ou en attente couvrant la neuromodulation vagale, la régulation du glucose, l’intelligence artificielle et les applications compatibles Bluetooth.
ReShape Lifesciences (RSLS) hat eine Zulassungsmitteilung vom USPTO für die Patentanmeldung 18/069,689 mit dem Titel 'Hochfrequente Muster mit niedrigem Tastverhältnis zur neuronalen Regulation' erhalten, die Schutz bis August 2037 bietet. Das Patent umfasst ihr Diabetes-Neuromodulationssystem, das die proprietäre vBloc™-Technologie zur Behandlung von Typ-2-Diabetes durch Vagusnervmodulation nutzt.
Die Technologie zeichnet sich durch einen energieeffizienten Algorithmus aus, der diskontinuierliche Hochfrequenzsignale mit verflochtenen Mikro- und Millisekundenpausen verwendet und dabei 10-mal weniger Energie verbraucht als herkömmliche kontinuierliche Signale. Präklinische Tests an Rattenvagusnerven zeigten eine gleichwertige Wirksamkeit und bleiben mit standardmäßigen implantierbaren Pulsgeneratoren kompatibel.
Das geistige Eigentumsportfolio des Unternehmens umfasst 63 erteilte oder anhängige Patente, die vagale Neuromodulation, Glukoseregulierung, Künstliche Intelligenz und Bluetooth-fähige Anwendungen abdecken.
- Patent protection secured until 2037 for diabetes neuromodulation technology
- 90% reduction in energy consumption compared to current devices
- Successful completion of preclinical development with proven efficacy
- Strong IP portfolio with 63 issued or pending patents
- Technology compatible with standard implantable pulse generators, reducing development costs
- Technology still in preclinical phase, requiring further development and testing
- Commercial viability and market adoption yet to be proven
Insights
ReShape's new diabetes neuromodulation patent strengthens IP portfolio with energy-efficient technology that could reduce treatment costs for Type 2 diabetes.
ReShape Lifesciences has secured a Notice of Allowance for a patent covering an innovative approach to diabetes treatment through vagal neuromodulation. The technology combines vagus nerve block (vBloc™) with vagus nerve stimulation to regulate blood glucose by modulating signals to the liver and pancreas.
What distinguishes this technology is its remarkable energy efficiency. The patented method uses discontinuous high-frequency signals with interwoven micro- and millisecond pauses, creating what they describe as an energy-efficient algorithm that "taps" the nerve with bursts of stimulation. This approach consumes
The energy efficiency translates to practical benefits: smaller batteries, more compact devices, and longer intervals between charges—all critical factors for patient comfort and adoption. Additionally, the technology's compatibility with standard implantable pulse generators enables cost-effective development, potentially lowering the barriers to bringing this solution to market.
While still in preclinical stages, this patent (valid until August 2037) strengthens ReShape's position in the bioelectronic medicine space for metabolic disorders. The company now has 63 issued or pending patents spanning vagal neuromodulation, glucose regulation, AI, and Bluetooth applications, creating a robust intellectual property foundation for their diabetes treatment approach.
Patent allowance extends ReShape's IP protection until 2037, significantly enhancing their competitive position in the diabetes neuromodulation market.
This Notice of Allowance from the USPTO represents a substantial enhancement to ReShape Lifesciences' intellectual property portfolio. Patent application 18/069,689, titled "High-Frequency Low Duty Cycle Patterns for Neural Regulation," will provide protection until August 4, 2037, securing more than 12 years of market exclusivity for their energy-efficient neuromodulation approach.
The timing is strategically significant, coming shortly after another Notice of Allowance received in March, suggesting accelerating momentum in expanding their IP footprint. For a micro-cap company with a market capitalization of approximately
The patent's focus on achieving equivalent efficacy with
The compatibility with standard implantable pulse generators is particularly astute from a commercialization perspective. Rather than requiring entirely custom hardware, this approach leverages existing medical device infrastructure, potentially accelerating development timelines and reducing regulatory hurdles.
With a portfolio now comprising 63 issued or pending patents across vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth applications, ReShape has constructed a formidable protective moat around their diabetes neuromodulation technology, creating multiple potential pathways for commercialization while deterring competitive encroachment.
Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia
Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device
Fully Compatible with Standard Implantable Pulse Generators, Enabling Cost-Effective Development
IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/069,689, entitled, “High-Frequency Low Duty Cycle Patterns for Neural Regulation.” When issued, the patent will provide protection until August 4, 2037. The Diabetes Neuromodulation system leverages its proprietary vagus nerve block (vBloc™) technology platform, along with vagus nerve stimulation, to treat Type 2 diabetes, a prominent disorder linked with obesity.
“Type 2 diabetes remains a global health challenge and continues to be difficult to treat effectively, despite the range of available medications, surgical options, and dietary interventions,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences®. “Our Diabetes Neuromodulation technology addresses this by regulating blood glucose through targeted vagal nerve modulation, specifically, blocking and stimulating signals to the liver and pancreas. This patent will cover discontinuous high-frequency signals with interwoven micro- and millisecond pauses, forming an energy-efficient algorithm that ‘taps’ the nerve with bursts of stimulation to achieve a blocking effect. By using approximately 10 times less energy than traditional continuous signals, the system enables the use of smaller batteries or devices and allows for longer intervals between charges. Preclinical testing on rat vagus nerves has demonstrated equivalent efficacy to continuous signals, while remaining fully compatible with standard implantable pulse generators, which will allow for cost-effective development. To date, our team has successfully completed preclinical development, harnessing bioelectronic technology to personalize treatment, boost insulin production, and manage blood glucose levels. This innovation shows strong promise for the treatment of both type 2 diabetes and hypoglycemia.”
“The recent allowance of this patent—coming shortly after the Notice of Allowance received in March—further reinforces the promise of our groundbreaking Neuromodulation technology. Designed to personalize diabetes management, this innovation has demonstrated the potential to reduce reliance on medications by optimizing glucose control. In doing so, it aims to lower overall treatment costs and decrease complications associated with poor blood sugar management and medication non-compliance,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “Similar to other patent families within ReShape, the Diabetes Neuromodulation technology is backed by a strong intellectual property portfolio, consisting of 63 issued or pending patents. These patents span key areas such as vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth-enabled applications—collectively securing a clear path to commercialization and offering robust protection against competitive threats.”
About The ReShape Diabetes Neuromodulation Device
The ReShape Diabetes Neuromodulation system (formerly, Diabetes Bloc-Stim Neuromodulation™) (DBSN™) is a novel minimally invasive therapeutic implant concept that delivers bio-electronic neuromodulation of vagus nerve branches that are innervating organs which regulate plasma glucose. The system stimulates vagus celiac fibers of the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance following ligation. The system utilizes a proprietary, reversable and adjustable electrical blockade that may represent the future of personalized medicine. Reshape Lifesciences believes its system is superior to both standalone stimulation of the vagus nerve, and vagus nerve ligation which has undesirable side effects and causes irreversible damage to the nerve.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® and Lap-Band® 2.0 Flex Systems provide minimally invasive, long-term treatment of obesity and are an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
As previously announced ReShape has entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., pursuant to which ReShape has agreed to sell substantially all of its assets to Biorad (or an affiliate thereof), including ReShape’s Lap-Band® System, Obalon® Gastric Balloon System and the DBSN™ system (but excluding cash). Therefore, at the closing of the transactions contemplated by the asset purchase agreement, the DBSN™ system will be owned by Biorad.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the promise of the Diabetes Neuromodulation technology and the potential path to commercialization of the technology. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com
FAQ
What is the energy efficiency improvement in RSLS's new diabetes neuromodulation patent?
How long will ReShape Lifesciences' new diabetes neuromodulation patent protection last?
What are the key benefits of RSLS's new diabetes treatment technology?
How many patents does ReShape Lifesciences currently have in its portfolio?
What stage of development is RSLS's Diabetes Neuromodulation system currently in?
